期刊文献+

临床下一代测序的自动化与常规化专家共识

Chinese Expert Consensus on Automation and Routine Sequencing of Next-Generation Sequencing in Clinical Practice
下载PDF
导出
摘要 下一代测序(NGS)应用于临床十余年以来,至今尚未能形成成熟的自动化与常规化检测手段。本共识面向临床NGS检测的学科和应用,根据临床NGS应用的现状,结合国内外相关检测产品、共识规范以及临床的实际需求,针对临床NGS自动化与常规化的建设路径,形成专家共识,给出相关建议,旨在推动临床NGS技术的进一步推广及应用,提高我国临床NGS的整体水平以及为精准医疗服务的效率。 The matured automatically and routinely detection methods have not been generated since the over decade application of next-generation sequencing(NGS)in clinical practice.This consensus is oriented to the disciplines and applications of clinical NGS testing and provided relevant advices of constructing automatically and routinely path of clinical NGS,which was based on the current clinical application states and combined related testing products,consensus specifications and actual clinical demands from domestic and abroad.The consensus aimed at spreading the application,and promoting the entire level and the efficiency of precision medical services of clinical NGS in China.
作者 中国生物医学工程学会医学检验工程分会 康熙雄 Laboratory Medicine Engineering Branch of Chinese Society of Biomedical Engineering
出处 《中国生物医学工程学报》 CAS CSCD 北大核心 2023年第6期641-650,共10页 Chinese Journal of Biomedical Engineering
关键词 临床基因检测 下一代测序 常规化 自动化 clinical genetic testing next-generation sequencing automatization
  • 相关文献

参考文献19

二级参考文献92

  • 1张建平,王治国.临床检验室间质量评价计划主要问题以及研究进展[J].中华检验医学杂志,2007,30(9):977-981. 被引量:33
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics [ J]. CA Cancer J Clin, 2011,61 : 69-90.
  • 3Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008 [ J]. Int J Cancer, 2010, 127 : 2893-2917.
  • 4Giaccone G, Gallegos Ruiz M, Le Chevalier T, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a ohase Ⅱ studv[J]. Clin Cancer Res, 2006, 12: 6049-6055.
  • 5Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation[ J]. Lung Cancer, 2012, 77 : 460-463.
  • 6Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China [J]. Lung Cancer, 2012, 77: 371-375.
  • 7Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from 1PASS, a phase Ⅲ study of gefitiuib or carboplatin/paclitaxel in non-small cell lung cancer[ J]. J Thorac Oncol, 2012, 7 : 115- 121.
  • 8Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor ( WJTOG3405 ) : an open label, randomised phase 3 trim [ J ]. Lancet Oncol, 2010, 11 : 121-128.
  • 9Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J]. N Engl J Med, 2010, 362: 2380-2388.
  • 10Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer ( OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study [ J ]. Lancet Oncol, 2011, 12: 735-742.

共引文献643

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部